Early in the pandemic, doctors in China and Italy recognized the...

Early in the pandemic, doctors in China and Italy recognized the telltale signs of a body in cytokine shock — fever, a racing heart and plummeting blood pressure — and treated patients with the drug tocilizumab. That drug is marketed by Roche as Actemra.

Anecdotal evidence and preliminary trials soon confirmed their hunch. Since then, studies have shown that high levels of IL-6 portend respiratory failure and death, and that Actemra lowers these risks.

Other drugs that quell IL-6 activity have shown promising results, as has Kineret, a drug that quiets a different cytokine called IL-1.

A more efficient solution than blocking any single cytokine would be to break the cycle of inflammation at its origin experts say and nothing exists apparently.

Veyonda has potent anti-inflammatory properties through inhibition of STING signalling, a signalling pathway thought to fuel toxic inflammation and tissue damage in patients with low oxygen level.5 While further studies are ongoing to implicate this pathway, the observation that none of the key biomarkers identified as being associated with increasing severity of COVID-19 disease1,2 were increased after initiation of Veyonda treatment, is consistent with the antiinflammatory effects of Veyonda.

Means?

nothing right now exists commercially anywhere on this planet.

Veyonda is a company maker IMO and if confirmed its a $20 stock minimum